<u>Capturing the Patient Journey using Electronic</u> <u>Patient Reported Outcome Measures (ePROMs)</u> <u>in Cutaneous Lymphomas</u>



Nicholas Lawrance, Nina Farquharson, Eileen Parry, Christina Hague, Richard Cowan

The Christie NHS Foundation Trust, University of Manchester

WCCL April 12th 2024



Disclosures

Kyowa Kirin Medical Advisor



ePROMs in Cutaneous Lymphoma

- Electronic system with the ability to capture the impact on QoL for our patients with Cutaneous Lymphoma
- Patients are invited to complete questionnaires in their home surroundings in their own time (in discussion with their carers)
- The responses are available for the clinician to review prior to seeing the patient in the clinic
- The patient responses are permanently captured in the electronic patient record



ePROMs in Cutaneous Lymphoma

- The ePROMS questionnaire comprises :
 - Skindex-16. 3 domains:
 - symptoms, emotion and function
 - EuroQol EQ-5D-5L
 - Section for free text: "Is there anything else you would like your consultant to know?"
 - Sent via text message 5 days prior to clinic appointment



Patient experience-Questionnaire





Patient view

The below set of questions ask about your symptoms from your skin.

Please select the number most applicable to you on a scale of 0 - 6. Where:

0 means Never Bothered and 6 means Always Bothered

Your skin condition itching	2	Dr.
Your skin condition burning or stinging	2	-0
Your skin condition hurting	2	
Your skin condition being irritated	3	
The persistence/reoccurrence of your skin condition	5	



skin condition

ePROMS feasibility and evaluation

- 2021 feasibility study
 - 76% response rate
- Structured interviews to assess patient and clinician perspective:
 - 19 patients
 - 3 clinicians interviewed
- Patients :
 - Positive responses
 - Barriers: included lack of smartphone or internet access
- Clinicians
 - Extra time in reviewing the ePROMs prior to seeing the patient (improved with familiarity)

Crooks GJ, et al. European Journal of Cancer. 2021;156:S66-S67.



THESE QUESTIONS CONCERN THE SKIN CONDITION WHICH HAS BOTHERED YOU THE MOST DURING THE PAST 7 DAYS

II.	ring the past 7 days, how often ve you been bothered by:	Never Bothered ↓			•			vays nered V
1.	Your skin condition itching		□₁		□₃	□₄	□s	
2.	Your skin condition burning or stinging	□。	□₁		Пз	□₄	□₅	□6
3.	Your skin condition hurting	□。	□₁	\square_2	□₃	□₄	□s	
4.	Your skin condition being irritated	□。	□₁	\square_2	Пз	□₄	□ ₅	□6
5.	The persistence / reoccurrence of your skin condition $\underline{\ }$	□。	□₁		Пз	□₄	□₅	□6
6.	Worry about your skin condition(For example: that it will spread, get worse, scar, be unpredictable, etc)	□。	□₁		□з	□₄	□s	□6
7.	The appearance of your skin condition $_$	□。	□₁	\square_2	Пз	□₄	□₅	\square_6
8.	Frustration about your skin condition	□。	□₁	\square_2	Пз	□₄	□s	□6
9.	Embarrassment about your skin condition	□。	□₁	\square_2	Пз	□₄	□₅	□6
10.	Being annoyed about your skin condition $_$	□。	□₁	\square_2	□₃	□₄	□₅	□₅
11.	Feeling depressed about your skin condition	□。	□₁		□₃	□₄	□s	□6
12.	The effects of your skin condition on your interactions with others _(For example: interactions with family, friends, close relationships, etc)	□₀	□₁	\square_2	□₃	□₄	□₅	□ ₆
13.	The effects of your skin condition on your desire to be with people	□₀	□₁	\square_2	□₃	□₄	□s	□6
14.	Your skin condition making it hard to show affection .	□。	□₁	\square_2	Пз	□₄	□ ₅	□₅
15.	The effects of your skin condition on your daily activities .	□。	□₁	\square_2	Пз	□4	□₅	□6
16.	Your skin condition making it hard to work or do what you enjoy	□。	□₁		۵	□₄	□s	□ 6

Have you answered every item? Yes ☐ No ☐

Under each heading, please tick the ONE box that best describes your health TODAY.

MOBILITY

I have no problems in walking about I have slight problems in walking about I have moderate problems in walking about I have severe problems in walking about I am unable to walk about	
SELF-CARE I have no problems washing or dressing myself I have slight problems washing or dressing myself I have moderate problems washing or dressing myself I have severe problems washing or dressing myself I am unable to wash or dress myself	
USUAL ACTIVITIES (e.g. work, study, housework, family or leisure activities) I have no problems doing my usual activities I have slight problems doing my usual activities I have moderate problems doing my usual activities I have severe problems doing my usual activities I am unable to do my usual activities	
PAIN / DISCOMFORT I have no pain or discomfort I have slight pain or discomfort I have moderate pain or discomfort I have severe pain or discomfort I have extreme pain or discomfort	
ANXIETY / DEPRESSION I am not anxious or depressed I am slightly anxious or depressed I am moderately anxious or depressed I am severely anxious or depressed I am extremely anxious or depressed	



ePROMs in Cutaneous Lymphoma

Dec 2020 – September 2023


208 patients

- 69% Male
- Age 65 (28 95)
- MF = 107
- SS = 15
- B Cell 46
- Others 40
- 70% of MF early stage

- 153 completed more than one form (2 – 16)
- 36 patients filled in the questionnaire 5 or more times




Mean overall health score for all patients





Skindex-16 – Diagnosis Category






Skindex 16

Skindex_16	Diagnosis Category	Min	1st Quartile	Median	Mean	3rd Quartile	Max	Kruskal-Wallis Test P value
	MF or SS	0	17	45	44.17	67	100	
Emotions	PCMZL or PCFCL	0	0	7	19.80	36.25	93	<0.0001
	Others	0	0	16.5	33.15	64.75	100	
	MF or SS	0	0	13	22.42	37	100	
Functioning	PCMZL or PCFCL	0	0	0	6.70	0	67	<0.0001
	Others	0	0	1.5	14.05	20.75	83	
	MF or SS	0	6	17	25.80	39	100	
Symptoms	PCMZL or PCFCL	0	0	6	14.72	17	83	0.0105
	Others	0	0	14	18.05	28	83	



Skindex-16 – Early/Late Stage





ePROMs Scoring

Skindex- 16- Higher scores are worse

EQ5D Lower scores are worse

For analysis:


Mild: Score 0, 1 or 2

Severe: Score 3, 4, 5, 6



		Skinday 16 Hama		MF or SS (122)				
		Skindex-16 Items	Mild		Severe			
us	1	Your_skin_condition_itching	71	58.2%	51	41.8%		
Symptoms	2	Your_skin_condition_burning_or_stinging	94	77.0%	28	23.0%		
Syl	3	Your_skin_condition_hurting	101	82.8%	21	17.2%		
	5	The_persistencereoccurrence_of_your_skin_condition	47	38.5%	75	61.5%		
	6	Worry_about_your_skin_condition	53	43.4%	69	56.6%		
	7	The_appearance_of_your_skin_condition	51	41.8%	71	58.2%		
Emotions	8	Frustration_about_your_skin_condition	54	44.3%	68	55.7%		
E	9	Embarrassment_about_your_skin_condition	70	57.4%	52	42.6%		
	10	Being_annoyed_about_your_skin_condition	66	54.1%	56	45.9%		
	11	Feeling_depressed_about_your_skin_condition	71	58.2%	51	41.8%		
	12	The_effects_of_your_skin_condition_on_your_interactions_with_others	95	77.9%	27	22.1%		
gui	13	The_effects_of_your_skin_condition_on_your_desireto_be_with_people	95	77.9%	27	22.1%		
ctioning	14	Your_skin_condition_making_it_hard_to_show_affection	98	80.3%	24	19.7%		
Functi	15	The_effects_of_your_skin_condition_on_your_daily_activities	87	71.3%	35	28.7%		
	16	Your_skin_condition_making_it_hard_to_work_or_do_what_you_enjoy	83	68.0%	39	32.0%		

EQ5D questionnaire





Practical Limitations

Patient requires access to appropriate technology

 May increase time spent reviewing responses prior to seeing patients



Results summary

Over 40% patients with MF and SS suffer distressing itch

 42 % - 62% patients with MF and SS report significant psychological symptoms

 The SS patient cohort experience a greater symptomatic and psychological impact than MF



Results summary

- Indolent cutaneous B cell lymphomas report significantly better quality of life than MF/SS
- Late stage disease have worse quality of life scores than early stage disease
- No significant difference by gender or age



Future potential of ePROMs

- Embedded in the routine assessment and management of patients automatically recording the responses in the patient record
- Dynamic assessment of impact of disease on the patient
 - Analysis of change over time
 - Response to treatment
 - Comparisons in clinical trials
- Allows remote virtual assessment
 - Determining the frequency and format follow up
 - Tailor support for patients between out patient visits



Thank you





Dr Christina Hague, Dr Nina Farquarson, Dr Nick Lawrance



Our initial data does not show significant difference in skindex 16 by gender or age

